drugset
drugset / Trial / NCT02043288

Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer

NCT02043288 ↗

Phase 3 Completed 310 enrolled Orient Europharma Co., Ltd. NanoCarrier Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This clinical trial is designed to evaluate the impact of the addition of NC-6004 to gemcitabine in the treatment of patients with locally advanced or metastatic pancreatic cancer in Asian countries.

Timeline

Start
2014-01
Primary completion
2019-12
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject NC-6004 Other / unclassified 90 mg/m2 Intravenous

Indications

malignant pancreatic neoplasm